|
|
||||||||
1From the Health Research and Education Center, Washington State University Spokane, Spokane, Washington; the 2Center for Genetic Eye Diseases, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio; the 3Medical Genetics Unit, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon; the 4Department of Ophthalmology and Visual Sciences, University of Utah Health Sciences Center, Salt Lake City, Utah; the 5Departments of Molecular and Human Genetics, 6Medicine, and 7Ophthalmology, Baylor College of Medicine, Houston, Texas; and the 8Sacred Heart Medical Center, Spokane, Washington.
| Abstract |
|---|
|
|
|---|
METHODS. A genome-wide screen, linkage analysis in the PITX3 chromosomal region 10q25, haplotype analysis, and sequencing of the PITX3 gene were performed on 28 affected and 14 unaffected member of a three-generation Lebanese family.
RESULTS. Genome-wide linkage analysis showed a lod score of 3.56 at
= 0.00 on chromosome 10 at area q25. Analysis of the haplotypes and phenotypes confined the disease locus to a region on 10q25 between the markers D10S1239 and D10S1268. A candidate gene, PITX3, maps to that region. Sequencing of the PITX3 gene revealed a heterozygous G deletion mutation in 25 of the 42 family members. In addition, two siblings from a consanguineous marriage were found to be homozygous for the deletion.
CONCLUSIONS. This is the first report of homozygous PITX3 mutations in humans. The phenotype in these individuals highlights the role of PITX3 in ocular and central nervous system (CNS) development.
A(S13N)4 ; a deletion of a single nucleotide (650delG)3 ; and a 17-bp insertion (656ins17, described elsewhere as 657-673dup17),3 4 the last two affecting the C-terminal portion of the protein. Also, two deletions have been described in the mouse, one of 652 bp in the 5' untranslated region (UTR) and the other of 1423 bp in the proximal promoter and exon 1 of Pitx3, in the homozygous aphakia (ak) mouse in which they cause microphthalmia and arrest in lens development.5 6 Pitx3 is expressed in the developing lens, skeletal muscle, and dopaminergic neurons of the substantia nigra in the brain.7 Neurons in the substantia nigra are responsible for fine movement control. It has recently been demonstrated that the ak mouse also has an abnormal profile in the output of some spatial movements.8 To date, there have been no reports of humans homozygous or compound heterozygous for PITX3 mutations.
Here we report a three-generation Lebanese family with posterior polar cataract (PPC) in 28 affected individuals and a mutation in PITX3 (650delG) that cosegregates with the disease. In addition, two brothers from a consanguineous mating were found to be homozygous for the deletion and showed a more severe ocular and neurologic phenotype, with severe microphthalmia and neurologic deficits. This is the first report of human homozygosity for a mutation in PITX3 and the first evidence of the involvement of this gene in human neurologic development.
| Methods |
|---|
|
|
|---|
Markers and Genotyping
Genotyping was performed (PRISM Linkage Mapping Set ver. 2.5, MD10; Applied Biosystems, Inc. [ABI], Foster City, CA) for the whole genome according to the manufacturers recommendations. Selected markers were chosen from chromosome 10, area q25, according to the Ensembl Genome Browser (http://www.ensembl.org9 ) and their chromosomal positions were confirmed on the sequence of the SuperContig NT_030059 (accession number ENSG00000107859). Marker information and primers were obtained from UniSTS (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unists/ provided in the public domain the National Center for Biotechnology Information, Bethesda, MD). We designed a new polymorphic marker, Ch10cat2, positioned between markers D10S1266 and D10S1265. The primers for Ch10cat2 are: forward 5'-CACAGAGACACAGGCAAAGGC-3'; reverse 5'-GCTGTGTGTACGCATCTCTGTTTTG-3'. The observed PCR product size range was 113 to 129 bp. The amplification reactions were performed in a thermal cycler (GeneAmp PCR system 9700; Perkin Elmer, Wellesley, MA). The amplified products were visualized on a sequencer (3100 Sequencer; ABI) according to the manufacturers recommendations. The data were analyzed on computer (Genotyper 3.7; ABI). The Mendelian inheritance was confirmed with PedCheck ver. 1.1 software (http://watson.hgen.pitt.edu/register/docs/pedcheck.html/ developed by Jeff OConnell, University of Pittsburgh, Pittsburgh, PA).
Linkage Analysis
Linkage analysis was performed on the genome-wide genotype data and identified a positive lod score of 3.56 (
= 0.00) to the marker D10S2470 on chromosome 10q25. This region was investigated with a more detailed analysis. The genotypes from 22 published and custom-designed markers in the critical region were analyzed with conventional parametric two-point linkage analysis using the FASTLINK program suite (http://softlib.cs.rice.edu/ provided in the public domain by Rice University, Houston, TX). A dominant model of inheritance with 90% penetrance in both heterozygous and homozygous individuals was used with a disease allele frequency of 0.001, followed by multipoint analysis using Allegro.10 To accomplish this with Allegros constraints on family size, the large pedigree was broken down into seven subpedigrees. Tabular and graphic two-point and multipoint linkage data were inspected to establish the most likely region with the gene.
Mutation Analysis
PCR primers were designed to amplify and sequence the exons and intronexon junctions of all four coding exons of PITX3, according to GenBank (http://www.ncbi.nlm.nih.gov/GenBank/ provided in the public domain by NCBI). Their sequences are in Table 1 . Also, PCR primers were designed to amplify and to sequence a 1-kb region, including the 5'-UTR upstream of the exon 1 translation start site and the 3'-UTR of exon 4. Their sequences are in Table 1 . All amplification reactions were performed with standard PCR conditions in the thermal cycler (GeneAmp PCR system 9700; Perkin Elmer). The amplified products were purified (QIAquick PCR Purification Kit; Qiagen, Valencia, CA) and sequenced (BigDye Terminator Cycle Sequencing Ready Reaction; DNA sequencing kit; ABI) in the forward and reverse directions, according to the manufacturers recommendations. Sequencing results were visualized (3100 Sequencer; ABI). according to the manufacturers recommendations. The data were analyzed on computer (Sequencher ver. 3.1.1 software; Gene Codes, Ann Arbor, MI).
|
| Results |
|---|
|
|
|---|
= 0.00) with marker D10S2470 on chromosome 10, region q25 (data not shown). Follow-up linkage analysis with 28 affected and 14 unaffected family members in the 10q25 region increased the lod score to 6.56 (
= 0.00) with marker D10S1268 (Table 2) .
|
|
|
|
|
Their ocular abnormalities and blindness were noted in the first 3 months of life, but significant physical disability became apparent only by the age of 15 to 18 months when they failed to walk. They also had a significant delay in speech development. By the age of 4 to 6 years they started having abnormal movements of their head and upper limbs and contractures in flexion of the knees. They acquired sphincter control at approximately age 10. Their encephalopathies were described as static, and they showed no signs of neurologic deterioration over the past two decades. On neurologic examination, they showed major disequilibrium when forced to stand upright. The knees were flexed with severe contractures of the hamstring muscles. They could not understand orders of medium complexity. There were choreiform movements of the head and upper limbs and to a lesser extent, of the trunk. The upper body and limb tone was normal, but increased with contractures in the lower limbs. Reflexes were present but weak. There was no clear-cut response of plantar reflex (withdrawing of the foot, lack of cooperation). No sensory abnormalities were detectable, except blindness. Cerebellar functions were not assessable because of lack of cooperation. Vital signs were normal. Their clinical course had not shown any significant progressive deterioration over the past two decades, according to their parents. Some stereotypic behavior, such as eye-rubbing in the older brother and hitting of the face in the younger, was observed. The older brother had bilateral valgus deformities of the ankle joints. The younger brother was slightly less severely affected. Magnetic resonance imaging (MRI) of the brain in both brothers was normal except for the presence of optic nerve thinning and small globes.
| Discussion |
|---|
|
|
|---|
PITX3 is a paired-like homeodomain transcription factor that belongs to the RIEG/PITX homeobox gene family.12 The 650delG and the 656ins17 mutations in PITX3 are close to one another and affect the C-terminal region of the gene. The 650delG mutation is 86-amino-acid residues upstream of the C terminus of the PITX3 protein. Although this region does not include the homeodomain, it is predicted that the resultant peptide lacks a 14-amino-acid motif identified within the C-terminal region of at least 40 paired class homeobox transcription factors and named the OAR domain.14 Although the function of the domain is not well understood, mutations in the OAR domain of Pitx2, a gene associated with Rieger syndrome in humans, suggest a transactivation regulatory role by inhibiting DNA binding and promoting interaction with other transcription factors.15 16 17 Also, it was demonstrated for the Prx1a homeoprotein, that the OAR domain inhibits transactivation,18 and, in the Cart1 homeoprotein, the domain serves as an intramolecular switch of its transactivation activity.19 However, RNA microinjection experiments with other bicoidclass homeobox genes like Xrx1 (the Xenopus homologue to RAX) have demonstrated that the absence of the OAR domain can cause a passive repression of the downstream target genes.20
Because the human conditions described to date for PITX3 mutations are autosomal dominant, the phenotypes have been attributed to haploinsufficiency.4 Nevertheless, as deletion of the OAR domain leads to transcriptional activation in Pitx2,15 we cannot rule out the possibility that the mutation described herein induces transactivation instead of downregulation of target genes. Also, we cannot exclude the possibility that the mutation could result in a passive repression mechanism caused by the OAR-deleted PITX3 protein. Further experiments are needed to determine the specific role of the OAR domain in the function of PITX3.
The phenotype of the two siblings who were homozygous for the C-terminal deletion of PITX3 was much more severe than that of the heterozygous family members. In addition to having PPCs as in heterozygotes, the homozygous individuals had microphthalmia, blindness, and a neurologic disorder characterized by mental retardation, choreiform movements, and increased muscle tone and decreased deep tendon reflexes of the lower extremities. Imaging studies of the two homozygous siblings did not reveal any gross abnormalities of brain development; hence, it is likely that their neurologic syndrome is the result of cellular or interneuronal connection abnormalities. This phenotype, however, implies an essential role for PITX3 in normal ocular and CNS development.
Another paired box gene involved in eye and brain development, Pax6, has been found in homozygous state to produce phenotypic ocular and extraocular defects. Small eye (Sey) mouse is a homozygous mutant of Pax6 that lacks eyes, has craniofacial abnormalities, and dies soon after birth.21 Heterozygous mutations in PAX6 have been described in humans with aniridia and other ocular anomalies such as cataract and Peters anomaly.1 Compound heterozygous PAX6 mutations in humans have also been described with severe craniofacial and central CNS defects and no eyes.22 PAX6 appears to be a master control gene that synchronizes the events during the formation of the anterior eye and other central nervous structures.23 The target genes regulated by PITX3 are not yet established, though it seems to be an important key gene in the development of the eye and other tissues. Further studies are needed to elucidate the molecular role of this transcription factor in early development.
It was recently demonstrated in mice that Pitx3 is expressed in the mesencephalic dopaminergic (DA) neurons that are located in the ventral midbrain and that form the substantia nigra compacta (SNc) and the ventral tegmental area.8 The role of DA neurons is related to movement and behavior, and so they are a target for the understanding of the molecular mechanisms that underlie schizophrenia, addictive behavioral disorders, and Parkinsons disease.7 Moreover, Pitx3 defines the neuronal population required for spontaneous locomotor activity, and is involved in the specification of properties of DA neurons during terminal differentiation and maintenance.24 25 It has been demonstrated that the ak mice have no Pitx3 expression in the SNc and that in the absence of Pitx3, the DA neurons do not survive.26 Surprisingly, these mice have no motor defects, altered posture, waking pattern, or tremor, although they show aberrant behavior in a climbing test and lower overall motor activity levels.8 Both homozygous brothers in this report showed severe disorders of motor function, including inability to walk, chorea, and diplegia with flexion contractures of the lower limbs, in accordance with the role of PITX3 in movement skills and motor output capability, suggesting a role for PITX3, not only in anterior eye development and SNc differentiation and maintenance, but also in the CNS. In Parkinsons disease, there is a loss-of-function of adult SNc DA neurons, and the reason for this selective effect is unknown.7 The two patients with homozygous deletion in PITX3 did not show classic symptoms of early Parkinsons disease, but their clinical picture may be compatible with advanced Parkinsons disease.
The human ocular abnormalities found in the siblings with homozygous PITX3 mutations resembled those of the ak mouse. It is conceivable that the severe neurologic phenotype in these siblings is due to homozygous or heterozygous mutations at a locus unlinked to PITX3. This however is unlikely, however, because the four consanguineous marriages in the family produced eight offspring. Of these, only two individuals had neurologic abnormalities, and these were the two individuals who were homozygous for the PITX3 mutation. It is still possible that a locus that is closely linked to PITX3 is responsible for the neurologic phenotype in a recessive model, since these two children were the only ones who had a homozygous genotype at that putative locus. Although this is impossible to investigate at this point, it is an unlikely possibility, given the suspected role of PITX3 in brain development. Furthermore, the ocular and CNS phenotypes can be readily explained by the PITX3 expression pattern, which supports the contention that the phenotype is caused by the PITX3 mutation.
The neurologic phenotype of the two homozygous patients reveals a potential new role of PITX3 in the development of the nervous system that has not been described before in humans.
| Footnotes |
|---|
Submitted for publication August 18, 2005; revised November 15, 2005; accepted February 9, 2006.
Disclosure: C. Bidinost, None; M. Matsumoto, None; D. Chung, None; N. Salem, None; K. Zhang, None; D.W. Stockton, None; A. Khoury, None; A. Megarbane, None; B.A. Bejjani, None; E.I. Traboulsi, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Elias Traboulsi, Cole Eye Institute, Cleveland Clinic Foundation, i32, 9500 Euclid Avenue, Cleveland, OH 44195; traboue{at}ccf.org.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. Perveen, J. Favor, R.V. Jamieson, D.W. Ray, and G.C.M. Black A heterozygous c-Maf transactivation domain mutation causes congenital cataract and enhances target gene activation Hum. Mol. Genet., May 1, 2007; 16(9): 1030 - 1038. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |